Germany’s Grunenthal Shuffles Leadership Team As CEO Stock Departs
This article was originally published in The Pink Sheet Daily
Germany’s family-owned pain specialty company Grunenthal – already bracing for an expected fall in sales due to the loss of exclusivity on its best-selling product – now finds itself searching for a new CEO as well.
You may also be interested in...
Private Grünenthal Aims For Leadership In Pain
Family-owned Grünenthal GMBH has opened up to the outside world, significantly stepping up deal-making as it aims for "global innovation leadership" in pain management.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.